Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Chemical Works of Gedeon Richter EV-to-EBIT?
Chemical Works of Gedeon RichterRGEDF -4.68%94 EV-to-EBIT is 12.08 as of Jul. 22, 2026, which is 14% below its 10-year median of 14.01. GuruFocus rates RGEDF with a GF Score™ of 94/100 and a GF Value™ of $35.16 (Fairly Valued). The stock has 5 warning signs investors should review. Among 689 Drug Manufacturers companies, Chemical Works of Gedeon Richter ranks better than 60.38% on this metric.
Chemical Works of Gedeon Richter (OTCPK:RGEDF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Chemical Works of Gedeon Richter's Enterprise Value for the quarter that ended in Dec. 2025 was $4,934 Mil.
Chemical Works of Gedeon Richter's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $474 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter EV-to-EBIT Related Terms
Chemical Works of Gedeon Richter EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Chemical Works of Gedeon Richter's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemical Works of Gedeon Richter EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chemical Works of Gedeon Richter's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Chemical Works of Gedeon Richter's EV-to-EBIT falls into.
Chemical Works of Gedeon Richter's current Enterprise Value is $5,721 Mil.
Chemical Works of Gedeon Richter's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $474 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemical Works of Gedeon Richter (RGEDF) has a EV-to-EBIT of 12.08 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Chemical Works of Gedeon Richter and its competitors. This is 14% below median its historical median of 14.01. Over the past decade, Chemical Works of Gedeon Richter's EV-to-EBIT has ranged from 4.56 to 157.07. According to the industry distribution chart, Chemical Works of Gedeon Richter ranks #273 out of 689 companies in the Drug Manufacturers industry, placing it in the top 39.6%.
Is Chemical Works of Gedeon Richter's EV-to-EBIT too high?
Chemical Works of Gedeon Richter's current EV-to-EBIT of 12.08 is 14% below median its 10-year median of 14.01. Over the past 10 years, this metric has ranged from a low of 4.56 to a high of 157.07. The Drug Manufacturers industry median EV-to-EBIT is 15.95. Chemical Works of Gedeon Richter's value of 12.08 is 24.3% below this industry median. Based on the distribution chart, Chemical Works of Gedeon Richter ranks #273 out of 689 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Chemical Works of Gedeon Richter has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chemical Works of Gedeon Richter's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chemical Works of Gedeon Richter ranks #273 out of 689 companies for EV-to-EBIT. This puts Chemical Works of Gedeon Richter in the upper half of its industry. The industry median EV-to-EBIT is 15.95. Chemical Works of Gedeon Richter's value of 12.08 is 24.3% below this benchmark. Historically, Chemical Works of Gedeon Richter's own EV-to-EBIT has ranged from 4.56 to 157.07 over the past decade. While the company's 10-year median is 14.01 vs. the industry median of 15.95, Chemical Works of Gedeon Richter has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.95, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemical Works of Gedeon Richter's current EV-to-EBIT of 12.08 is 24.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Chemical Works of Gedeon Richter and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemical Works of Gedeon Richter's current EV-to-EBIT is 12.08, which is 14% below median its own 10-year median of 14.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemical Works of Gedeon Richter stock overvalued right now?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter (RGEDF) is currently considered Fairly Valued. The stock's GF Value™ is $35.16, compared to a current price of $36.51 — trading 3.8% above its estimated fair value. The current EV-to-EBIT is 12.08, which is 14% below median its 10-year median of 14.01 and 24.3% below the Drug Manufacturers industry median of 15.95. Chemical Works of Gedeon Richter's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Chemical Works of Gedeon Richter (RGEDF), the current EV-to-EBIT is 12.08 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemical Works of Gedeon Richter (RGEDF) Overvalued in 2026?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter stock appears to be overvalued.
The current stock price of $36.51 is trading 3.8% above its estimated GF Value™ of $35.16.
GuruFocus considers Chemical Works of Gedeon Richter to be Fairly Valued.
Key valuation signals for RGEDF:
EV-to-EBIT: 12.08 (14% below median its 10-year median of 14.01)
GF Value™: $35.16 vs. price of $36.51 (3.8% above fair value)
Industry Position: 24.3% below the Drug Manufacturers median (#273 of 689)
No single metric tells the full story. See the RGEDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemical Works of Gedeon Richter Business Description
Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women's Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.
94GF Score
Get the complete analysis for RGEDF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEDF has been successfully added to your 
